OncLive TV

Xiao Wei, MD, MAS, discusses the FDA approval of Pylarify TruVu for detecting PSMA-positive lesions in prostate cancer.

R. Lor Randall, MD, FACS, discusses how the BOOM consensus provides a global standard for managing complex infections in orthopedic oncology.

Amrita Krishnan, MD, discusses risk stratification in smoldering myeloma and factors that inform the classification of high-risk disease.

Kevin Kalinsky, MD, MS, FASCO, discusses the role of integrative oncology programs and the importance of survivorship clinics within cancer care.

Ranee Mehra, MD, highlights developments and ongoing questions regarding the evolving treatment paradigm for patients with head and neck cancer.

Sagar S. Patel, MD, discusses efficacy data for Orca-T with reduced intensity conditioning for hematologic malignancies from a retrospective analysis.

Jae Park, MD, discusses the importance and utility of MRD testing in the current acute lymphoblastic leukemia management field.

Jae Park, MD, discusses obe-cel in relapsed or refractory acute lymphoblastic leukemia and how new data are helping to shape its role.

Kevin Kalinsky, MD, MS, FASCO, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer.

Mitul Gandhi, MD, discusses data with epcoritamab in different racial subgroups of patients with relapsed/refractory diffuse large B-cell lymphoma.

Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.

Fred R. Hirsch, MD, PhD, discusses research validating an AI-assisted PD-L1 scoring algorithm against original Blueprint study data in lung cancer.

R. Lor Randall, MD, FACS, discusses global consensus on managing periprosthetic joint infections in sarcoma and complex bone reconstructions.

Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

Jessica Donington, MD, MSCR, discusses how the availability of targeted therapy has affected surgical decision-making in early-stage lung cancer.

C. Ola Landgren, MD, PhD, discusses evolving risk-stratification strategies in honor of Multiple Myeloma Awareness Month.

Sandip M. Prasad, MD, discusses future directions for investigating mitomycin intravesical solution in the ENVISION trial for NMIBC.

Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

Jorge Cortes, MD, discusses the variety of long-term patient goals in chronic myeloid leukemia and how prioritizing them leads to different TKI selections.

Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

Sandip M. Prasad, MD, details key findings from a post hoc analysis of CR rates and DOR in the phase 3 ENVISION trial.

During CRC Awareness Month, John L. Marshall, MD discusses whether the biology and origin of EO-CRC fundamentally differ from that of late-onset disease.

Sandip M. Prasad, MD, discusses prior data from the phase 3 ENVISION trial in NMIBC.

Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

David R. Wise, MD, PhD, discusses the safety profile of pasritamig plus docetaxel in patients with mCRPC.

Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormonal therapy decision-making in patients with early-stage, HR-positive breast cancer.

Multiple experts weigh in on the potential of MRD as a primary end point following recently issued FDA draft guidance for the end point in myeloma.

In honor of SCAC Awareness Day, Richard Kim, MD, discusses the shift toward personalized therapy and introduction of retifanlimab into the SCAC arsenal.

David R. Wise, MD, PhD, discusses the efficacy of pasritamig plus docetaxel in patients with mCRPC.

Rita Nanda, MD, discusses important research that has been conducted by the Translational Breast Cancer Research Consortium.